125 related articles for article (PubMed ID: 37369044)
1. Ultrasound features combined with tumor-infiltrating lymphocytes for prediction of pathological response to neoadjuvant chemotherapy in breast cancer.
Jia Y; Zhou X; Zhu Y; Song X; Duan Y; Chen K; Nie F
Med Ultrason; 2023 Jun; 25(2):131-138. PubMed ID: 37369044
[TBL] [Abstract][Full Text] [Related]
2. Contrast-free MRI quantitative parameters for early prediction of pathological response to neoadjuvant chemotherapy in breast cancer.
Du S; Gao S; Zhao R; Liu H; Wang Y; Qi X; Li S; Cao J; Zhang L
Eur Radiol; 2022 Aug; 32(8):5759-5772. PubMed ID: 35267091
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating Lymphocyte Score Based on FDG PET/CT for Predicting the Effect of Neoadjuvant Chemotherapy in Breast Cancer.
Sasada S; Kimura Y; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
Anticancer Res; 2020 Jun; 40(6):3395-3400. PubMed ID: 32487636
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound Strain Elastography and Contrast-Enhanced Ultrasound in Predicting the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: A Nomogram Integrating Ki-67 and Ultrasound Features.
Liu Q; Tang L; Chen M
J Ultrasound Med; 2022 Sep; 41(9):2191-2201. PubMed ID: 34888900
[TBL] [Abstract][Full Text] [Related]
6. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
Hamy AS; Pierga JY; Sabaila A; Laas E; Bonsang-Kitzis H; Laurent C; Vincent-Salomon A; Cottu P; Lerebours F; Rouzier R; Lae M; Reyal F
Ann Oncol; 2017 Sep; 28(9):2233-2240. PubMed ID: 28911063
[TBL] [Abstract][Full Text] [Related]
7. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
[TBL] [Abstract][Full Text] [Related]
8. The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively.
Kanou A; Masumoto N; Fukui K; Yokozaki M; Sasada S; Emi A; Kadoya T; Arihiro K; Okada M
J Med Ultrason (2001); 2022 Oct; 49(4):709-717. PubMed ID: 36002708
[TBL] [Abstract][Full Text] [Related]
9. Early Prediction of Response to Neoadjuvant Chemotherapy Using Dynamic Contrast-Enhanced MRI and Ultrasound in Breast Cancer.
Kim Y; Kim SH; Song BJ; Kang BJ; Yim KI; Lee A; Nam Y
Korean J Radiol; 2018; 19(4):682-691. PubMed ID: 29962874
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment ultrasound-based deep learning radiomics model for the early prediction of pathologic response to neoadjuvant chemotherapy in breast cancer.
Yu FH; Miao SM; Li CY; Hang J; Deng J; Ye XH; Liu Y
Eur Radiol; 2023 Aug; 33(8):5634-5644. PubMed ID: 36976336
[TBL] [Abstract][Full Text] [Related]
11. Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Erol VB; Goktas Aydin S; Bilici A; Cakir A; Acikgoz O; Olmez OF; Basim P
J Chemother; 2023 Nov; 35(7):662-670. PubMed ID: 37599454
[TBL] [Abstract][Full Text] [Related]
12. HER2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes.
Lee HJ; Lee JE; Jeong WG; Ki SY; Park MH; Lee JS; Nah YK; Lim HS
AJR Am J Roentgenol; 2022 Feb; 218(2):258-269. PubMed ID: 34431365
[No Abstract] [Full Text] [Related]
13. Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer.
Hong J; Rui W; Fei X; Chen X; Shen K
Cancer Med; 2021 Nov; 10(22):7921-7933. PubMed ID: 34562054
[TBL] [Abstract][Full Text] [Related]
14. Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer: The Role of Conventional Ultrasound and Contrast-Enhanced Ultrasound.
Jia Y; Zhu Y; Li T; Song X; Duan Y; Yang D; Nie F
J Ultrasound Med; 2023 Feb; 42(3):623-634. PubMed ID: 35866231
[TBL] [Abstract][Full Text] [Related]
15. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
16. Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs).
Kashiwagi S; Asano Y; Takada K; Goto W; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
Anticancer Res; 2022 Mar; 42(3):1421-1431. PubMed ID: 35220235
[TBL] [Abstract][Full Text] [Related]
17. Early prediction of pathological response to neoadjuvant chemotherapy of breast tumors: a comparative study using amide proton transfer-weighted, diffusion weighted and dynamic contrast enhanced MRI.
Zhang N; Song Q; Liang H; Wang Z; Wu Q; Zhang H; Zhang L; Liu A; Wang H; Wang J; Lin L
Front Med (Lausanne); 2024; 11():1295478. PubMed ID: 38298813
[TBL] [Abstract][Full Text] [Related]
18. Radiomic signatures derived from multiparametric MRI for the pretreatment prediction of response to neoadjuvant chemotherapy in breast cancer.
Bian T; Wu Z; Lin Q; Wang H; Ge Y; Duan S; Fu G; Cui C; Su X
Br J Radiol; 2020 Nov; 93(1115):20200287. PubMed ID: 32822542
[TBL] [Abstract][Full Text] [Related]
19. ALDH1 and tumor infiltrating lymphocytes as predictors for neoadjuvant chemotherapy response in breast cancer.
Lee A; Won KY; Lim SJ; Cho SY; Han SA; Park S; Song JY
Pathol Res Pract; 2018 May; 214(5):619-624. PubMed ID: 29685462
[TBL] [Abstract][Full Text] [Related]
20. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
